FIM
AQST icon

Frontier Investment Management’s Aquestive Therapeutics AQST Stock Holding History

Frontier Investment Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$53K Hold
11,000
– – ﹤0.01% 274
2020
Q1 		$24K Buy
+11,000
New +$41.8K ﹤0.01% 260

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Frontier Investment Management's AQST Position: Q2 2020 in Review

Frontier Investment Management held its Aquestive Therapeutics (AQST) position steady in Q2 2020 at 11,000 shares worth $53K. The position accounts for ﹤0.01% of the portfolio, ranked #274.

Frontier Investment Management first reported a position in AQST in Q1 2020 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold AQST as of Q2 2020.

  • Frontier Investment Management held 11,000 shares of Aquestive Therapeutics worth $53K as of Q2 2020.
  • Frontier Investment Management left its Aquestive Therapeutics share count unchanged in Q2 2020.
  • Aquestive Therapeutics made up ﹤0.01% of Frontier Investment Management's portfolio in Q2 2020, its #274 holding.
  • Frontier Investment Management first reported a position in Aquestive Therapeutics in Q1 2020 and has held it in 2 quarters since.
  • 57 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2020.

Based on Frontier Investment Management's 13F filing for Q2 2020, filed 11 Aug 2020.